Yamazhan T.Kurtaran B.Pullukçu H.Yüksel E.Özkaya D.Taşbakan M.I.Sipahi O.R.Durusoy R.Salih Zeki Aksu H.2019-10-272019-10-2720141120-009Xhttps://doi.org/10.1179/1973947813Y.0000000152https://hdl.handle.net/11454/26300In this study, we aimed to evaluate the 1-year post-treatment follow-up results of 112 patients who received pegylated interferon (PEG-IFN) for 52 weeks. HBeAg negativity/seroconversion and/or negative HBV-DNA at the end of the treatment were considered as response. Patients who had response at the end of treatment but had HBV-DNA breakthrough during 1-year follow-up were considered as relapse. The study group comprised 112 cases (34 HBeAg-positive, 78 HBeAg-negative). In HBeAg-positive and -negative cases, end-of-treatment response rates were 2.9% and 60.2%, whereas 1-year sustained virological response rates were 0 and 33.3%, respectively. When we compared relapse cases versus cases with response at the end of 1-year follow-up, being female and having low viral load were the two parameters associated with higher response rates (Chi-square, P50.028; Mann–Whitney U test, P50.023). Overall non-response rates to PEGIFN were high (57.1%). Results in HBeAg-positive cases were disappointing. © 2014 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia.en10.1179/1973947813Y.0000000152info:eu-repo/semantics/closedAccessChronic hepatitis BGenotypePegylated interferonsPrimary non-respondersSecondary non-respondersTreatment responseArticle26633934124171823Q3